Health Care Distributors

Shanghai Pharma

Shanghai Pharma's Changzhou Pharmaceutical Factory Rivaroxaban Tablets Approved for Thailand Market

Morgan Stanley Reports Q1 Earnings of Shanghai Pharmaceutical in Line with Expectations

Goldman Sachs Raises 2026-2028 Profit Forecast for Shanghai Pharmaceuticals but Maintains 'Sell' Rating

Shanghai Pharmaceutical Announces a 6.35% Increase in Profit to 1.418 Billion Yuan in Q1 2026

Shanghai Pharma released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 75.26 B (forecast CNY 74.17 B), actual EPS CNY 0.3823 (forecast CNY 0.3395)

Shanghai Pharma to release FY2026 Q1 earnings on April 29 After-Market BJT, forecast revenue CNY 74.17 B, EPS CNY 0.289

Shanghai Pharmaceutical Holding Co., Ltd. and Johnson & Johnson Reach National Full-Channel Strategic Cooperation on Long-Acting Injectable Medications for Schizophrenia

Shanghai Pharma released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 68.51 B (forecast CNY 65.91 B), actual EPS CNY 0.1513 (forecast CNY 0.0842)

Shanghai Pharma released FY2025 Annual Earnings on March 30 After-Market (BJT), Actual Revenue: CNY 283.58 B (Forecast: CNY 286.95 B), Actual EPS: CNY 0 (Forecast: CNY 1.5554)

Shanghai Pharma to release FY2025 earnings on March 30 After-Market BJT, forecast revenue CNY 286.95 B, EPS CNY 1.5554

Shanghai Pharmaceuticals' New Generation Direct Renin Inhibitor Enters Clinical Application

Shanghai Pharmaceutical's Subsidiary Qingchunbao Receives Clinical Trial Approval for Seven-Ingredient Fangji Huangqi Granules

Shanghai Pharmaceutical Obtains Registration Certificate for Pyridostigmine Bromide Oral Solution

Shanghai Pharmaceutical Smart Supply Chain Technology Co., Ltd. Established with a Registered Capital of 20 Million Yuan

Shanghai Pharmaceutical's Subsidiary's Sotalol Hydrochloride Tablets Pass Consistency Evaluation

Description of 2025 China Enterprise Science and Technology Innovation Power Ranking in Wholesale and Retail Industry

Shanghai Pharmaceutical Terminates Cooperation Agreement with Shengnuo Biotechnology for Novel Acid Inhibitor X842

Shanghai Pharmaceutical Subsidiary's Tramadol Hydrochloride Injection Passes Consistency Evaluation

HSBC Research Maintains Ratings for Shanghai Pharmaceuticals and Sinopharm with Target Price Adjustments

Shanghai Pharmaceuticals Subsidiary's Eslicarbazepine Acetate ANDA Approved by FDA

601607

M Stanley reported that SH PHARMAachieved 1Q revenue of RMB75.3 billion and net profit of RMB1.418 billion, both up 6.4% YoY, meeting expectations. The company is in talks with multinational firms in the US and EU for R&D opportunities. M Stanley maintains an Equalweight rating for SH PHARMAwith a target price of RMB18.8. Short selling data indicates a ratio of 20.386%.

AASTOCKS News

Morgan Stanley

SH PHARMA

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley: SH PHARMA  1Q Results In Line

02607

G Sachs has raised the target price for SH PHARMAfrom HKD10.3 to HKD10.63 while maintaining a Sell rating. The company reported a 6.4% YoY revenue increase to RMB75.3 billion and a net profit rise of 6.4% YoY to RMB1.4 billion, aligning with market expectations. The broker has adjusted net profit forecasts for 2026-2028 upwards by 5%, 3%, and 3.6%, respectively. However, profit margins may face pressure due to the normalization of volume-based procurement for generic drugs and medical devices.

Goldman Sachs

GS Hldg R

G Sachs Raises SH PHARMA  TP to HKD10.63, Maintains Sell Rating

512010

589720

159992

512290

510660

513120

159316

588860

520690

520880

SH PHARMAreported a 6.35% year-on-year increase in attributable net profit for 1Q26, reaching RMB1.418 billion. Operating revenue rose 6.36% to RMB75.262 billion, with pharmaceutical manufacturing sales up 15.64% and distribution sales up 5.52%. Basic EPS was RMB0.3823. R&D investment totaled RMB0.577 billion, accounting for 8.47% of industrial sales. After adjusting for non-recurring items, net profit was RMB1.238 billion, down 2.02% YoY. The company’s stock rose by 0.862%.

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ping An CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

SH PHARMA  1Q26 Attributable Net Profit Up 6.35% YoY

560600

159849

159938

159102

159929

Morgan Stanley has updated its risk-reward assessment on Shanghai Pharmaceuticals Holding, lowering its target price from HKD16 to HKD15.8 while maintaining an Overweight rating. The broker revised its earnings forecasts for 2026 to 2030 down by 2% to 3% due to a conservative revenue outlook. EPS is projected to reach RMB1.46 in 2026, RMB1.61 in 2027, and RMB1.72 in 2028.

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

GF CSI All Share Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Tianhong CNI BIOMEDICINE ETF

Hwabao WP CSI Pharmaceuticals ETF

Huaan Hang Seng Biotech ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal 800 Health Care ETF

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

M Stanley Cuts Shanghai Pharmaceuticals Holding  TP to HKD15.8, Rating Overweight

516930

Bank of America Securities raised the target price for Shanghai Pharma to HKD 14 and reiterated a "Buy" rating. The report noted that Shanghai Pharma's total revenue last year was RMB 283.6 billion, a year-on-year increase of 3%, in line with expectations. Due to overall pricing pressure, the bank lowered its sales forecasts for 2026 to 2028 to 2.7%, 5.8%, and 2.1%, respectively

AASTOCKS

Minsheng Royal CSI Biotechnology Theme ETF

Bank of America Securities raises Shanghai Pharma's target price to 14 yuan, reiterates "Buy"

Shanghai Pharma announced its 2025 annual performance, with revenue of RMB 283.58 billion, an increase of 3% year-on-year. It recorded a net profit of RMB 5.725 billion, a growth of 25.7%, with earnings per share of RMB 1.54. The final dividend is RMB 3.5 per 10 shares. After deducting one-time gains and losses, the net profit for the year was RMB 4.721 billion, a decline of 5.6%

"Performance" Shanghai Pharma's annual net profit is RMB 5.725 billion, an increase of 25.7%, with a dividend of RMB 3.5 per 10 shares

GlaxoSmithKline (GSK) has partnered with Shanghai Pharmaceutical to reintroduce its hepatitis B vaccine, Engerix B, to China after a four-year hiatus. The collaboration aims to utilize Shanghai Pharma's logistics and market resources to enhance vaccine accessibility. Although China's vaccination rate for newborns is high, adult vaccination remains low, with significant infection rates among those over 30. GSK, the largest global manufacturer of hepatitis B vaccines, seeks to improve adult vaccination rates as part of a broader shift in China's vaccination strategy.

Yicai

GlaxoSmithKline plc

SSE Health Care

UK's GSK Allies With Shanghai Pharma to Bring Hepatitis B Jab Back to China

Shanghai Pharma(601607.SH)

M Stanley: SH PHARMA 1Q Results In Line

G Sachs Raises SH PHARMA TP to HKD10.63, Maintains Sell Rating

SH PHARMA 1Q26 Attributable Net Profit Up 6.35% YoY

M Stanley Cuts Shanghai Pharmaceuticals Holding TP to HKD15.8, Rating Overweight

Bank of America Securities raises Shanghai Pharma's target price to 14 yuan, reiterates "Buy"

"Performance" Shanghai Pharma's annual net profit is RMB 5.725 billion, an increase of 25.7%, with a dividend of RMB 3.5 per 10 shares

UK's GSK Allies With Shanghai Pharma to Bring Hepatitis B Jab Back to China